Sanofi (SNYNF)
OTCMKTS
· Delayed Price · Currency is USD
98.00
+0.05 (0.05%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Total Vaccine | 8.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Vaccine Growth | -0.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dupixent | 13.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dupixent Growth | 18.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Neurology & Immunology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Neurology & Immunology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Oncology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Oncology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Blood Disorders | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Blood Disorders Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Core Assets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Core Assets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Non-Core Assets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Non-Core Assets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Industrial | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Industrial Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Care | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma | 32.78B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Other | -2.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccine Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccine Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -2.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Healthcare Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Healthcare Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Operating Income | 11.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Operating Income Growth | 1.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare (Post-2022 Reporting) Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other (Post-2022 Reporting) Operating Income | 58.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other (Post-2022 Reporting) Operating Income Growth | 687.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -2.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 19.99B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 7.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 9.03B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | -4.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World | 12.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Growth | -6.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|